BioClonal proudly participated in the PEGS Boston 2024 Summit, held from May 13th to 17th, where our CEO Paula and CSO Jessika represented the company at one of the most prestigious global conferences in antibody research. The event offered a unique platform for BioClonal to connect with industry leaders, exchange insights, and explore the latest breakthroughs in antibody development.
Throughout the summit, our company had the opportunity to network with fellow experts and discuss potential solutions for antibody development challenges. The team, eager to forge new partnerships, invited those facing obstacles in their projects to reach out and collaborate, emphasizing their commitment to driving innovation in the field.
BioClonal remains committed to pushing the boundaries of antibody innovation and looks forward to further collaborations in the coming year.